James Rolke - 10 Jan 2022 Form 3 Insider Report for REVELATION BIOSCIENCES, INC. (REVB)

Role
Chief Executive Officer, Director
Signature
/s/ J.P. Galda, as attorney-in-fact for James Rolke
Issuer symbol
REVB
Transactions as of
10 Jan 2022
Net transactions value
$0
Form type
3
Filing time
20 Jan 2022, 17:03:20 UTC
Next filing
28 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding REVB Common Stock 681,302 10 Jan 2022 Direct
holding REVB Common Stock 2,144 10 Jan 2022 By Spouse F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding REVB Restricted Stock Unit 10 Jan 2022 Common Stock 8,568 Direct F2, F3, F4
holding REVB Restricted Stock Unit 10 Jan 2022 Common Stock 65,050 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person disclaims beneficial ownership of shares held by the Reporting Person's spouse directly.
F2 These RSUs vest 25% on January 31, 2021, and thereafter quarterly over a three-year period.
F3 RSUs do not expire; they either vest or are canceled prior to vesting date.
F4 Each RSU converts into common stock on a one-for-one basis.
F5 These RSUs vest 25% on February 23, 2022, and thereafter monthly over a three-year period.

Remarks:

Exhibit 24 - Power of Attorney.